We are a near-commercial biotechnology company focused on oncology and autoimmune diseases, dedicated to translating scientific discoveries into innovative and accessible therapies for patients. Harnessing innovation as our edge and commercialization as our engine, we aim to become a sustainable and fully integrated biopharmaceutical company with end-to-end life-cycle capabilities, transforming scientific advances into meaningful patient benefits. Within these therapeutic areas, we strategically focus on developing highly differentiated oral small-molecule drug candidates to address significant unmet clinical needs in hematologic malignancies and autoimmune diseases. Enabled by our highly selective small-molecule drug discovery platform and our molecular glue discovery platform, we have established a pipeline that includes an NDA-stage drug candidate (bezacitinib), one registrational clinical stage candidate (CX1440), and five preclinical stage candidates (CX03, CX12, CX13, CX15 and CX16).